The 1st IPR Institution Decisions For Biosimilars
The first institution decisions for inter partes review in a biosimilars context were handed down by the Patent Trial and Appeal Board the week of July 13, 2015.[1] Boehringer Ingelheim Pharmaceuticals Inc. had...To view the full article, register now.
Already a subscriber? Click here to view full article